The University of Toledo

Faculty - Lawrence W. Elmer, M.D., Ph.D.

Professor of Neurology Director, The Center for Neurological Health Director, Parkinson's Disease and Movement Disorders Program email: lawrence.elmer@utoledo.edu SPECIAL INTERESTS  Parkinson's Disease Essential Tremor Huntington's Disease Tourette's Syndrome Parkinson's Plus Syndromes Stiff-Person Syndrome Dystonias Molecular basis of neurodegeneration Neuronal mitochondrial dysfunction and apoptosis EDUCATION M.D.: University of Florida, Gainesville, Florida, 1982-1987. Ph.D: University of Florida College of Medicine, Gainesville, Florida, 1982-1988. Medicine Residency: Sioux Falls V.A. Medical Center, Sioux Falls, South Dakota, 1988-1989. Neurology Residency: University of Michigan, Ann Arbor, Michigan, 1989-1992. Fellowship: Research Associate, Howard Hughes Medical Institute, University of Michigan, 1992-94.

PROFESSIONAL APPOINTMENTS

Lecturer in Movement Disorders: University of Michigan, 1992-1994.
Research Scientist: Ann Arbor VA Medical Center, 1994-1998.
Assistant Professor: University of Michigan, 1994-1998.
Assistant Professor: Medical University of Ohio, 1998-2009
Professor: University of Toledo (formerly Medical University of Ohio), 2009-present

CERTIFICATIONS

American Board of Psychiatry and Neurology, 1994

 

SOCIETY MEMBERSHIPS

American Academy of Neurology
New York Academy of Science
Society for Neuroscience

AWARDS

Dean's Award for Teaching Excellence, 2003
Golden Apple Teaching Award, MUO, 2003
Awarded Humanism in Medicine - MUO - Class of 2003, 2002
Named in list of America's Best Doctors, 2002
Teaching Scholar, Medical University of Ohio, 2000-01
Pfizer Scholar, 1995-97

EDITORIAL

AdHoc Reviewer for:
       Journal of Clinical Investigation, 1997
       Neurology Network Commentary, 1997

REPRESENTATIVE PUBLICATIONS

Shoulson I and the Parkinson Study Group. DATATOP: A decade of neuroprotective inquiry. Ann Neurol. 1998;44(Suppl 1):S160-S166.

Parkinson Study Group. A multicenter randomized controlled trial of remacemide hydrochloride as monotherapy for Parkinson’s disease. Neurology 2000; 54:1583-1588.
Shoulson, I and the Parkinson Study Group. A randomized controlled trial of remacemide for motor fluctuations in Parkinson’s disease. Neurology 2001; 56:455-462.

Little, KY, Elmer, LW, Zhong, H, Scheys JO, Zhang, L. Cocaine induction of dopamine transporter trafficking to the plasma membrane. Mol. Pharmacol. 2002; 61:436-445.

Pankratz, N, Nichols, WC, Uniacke, SK, Halter, C, Rudolph A, Shults, C, Conneally, PM, Foroud, T, and the Parkinson Study Group. Genome screen to identify susceptibility genes for Parkinson Disease in a sample without parkin mutations. Am. J. Hum. Genet. 2002; 71:124-135.

Nichols WC, Pankratz N, Uniacke SK, Pauciulo MW, Halter C, Rudolph A, Conneally PM, Foroud T, and the Parkinson Study Group. Linkage stratification and mutation analysis at the parkin locus identifies mutation positive Parkinson's disease families. J. Med. Genet. 2002; 39:489-492.

Shoulson I, Oakes D, Fahn S, Lang A, Langston JW, LeWitt P, Olanow CW,Penney JB, Tanner C, Kieburtz K, Rudolph A and the Parkinson Study Group. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl andtocopherol antioxidative therapy of parkinsonism trial.Ann Neurol. 2002 May;51(5):604-12.

Foroud T, Uniacke SK, Liu L, Pankratz N, Rudolph A, Halter C, Shults C, Marder K, Conneally PM, Nichols WC and the Parkinson Study Group. Heterozygosity for a mutation in the parkin gene leads to later onset Parkinson Disease. Neurology, in press.

Carson R. Reider, PhD, Cheryl A. Halter, MS, Peter F. Castelluccio, MS, David Oakes, PhD, William C. Nichols, PhD, Tatiana Foroud, PhD, and the Parkinson Study Group. Reliability of reported age at onset for Parkinson's disease, Movement Disorders, in press.